Federated Hermes Inc. Cuts Stake in United Therapeutics Co. (NASDAQ:UTHR)

Federated Hermes Inc. lowered its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 10.6% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 7,699 shares of the biotechnology company’s stock after selling 916 shares during the quarter. Federated Hermes Inc.’s holdings in United Therapeutics were worth $1,693,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the stock. Comerica Bank raised its stake in United Therapeutics by 2,697.2% in the 3rd quarter. Comerica Bank now owns 156,587 shares of the biotechnology company’s stock valued at $35,368,000 after acquiring an additional 150,989 shares during the period. Pacer Advisors Inc. increased its stake in shares of United Therapeutics by 27.6% in the fourth quarter. Pacer Advisors Inc. now owns 312,799 shares of the biotechnology company’s stock worth $68,781,000 after purchasing an additional 67,738 shares in the last quarter. Caisse DE Depot ET Placement DU Quebec raised its position in shares of United Therapeutics by 30.9% in the third quarter. Caisse DE Depot ET Placement DU Quebec now owns 260,412 shares of the biotechnology company’s stock valued at $58,819,000 after purchasing an additional 61,543 shares during the period. Glenmede Trust Co. NA lifted its stake in shares of United Therapeutics by 840.1% during the 3rd quarter. Glenmede Trust Co. NA now owns 68,098 shares of the biotechnology company’s stock valued at $15,381,000 after buying an additional 60,854 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. boosted its holdings in United Therapeutics by 125.2% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 87,048 shares of the biotechnology company’s stock worth $19,662,000 after buying an additional 48,397 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $238.26 on Tuesday. United Therapeutics Co. has a 52-week low of $204.44 and a 52-week high of $261.54. The company has a fifty day moving average of $234.21 and a 200-day moving average of $228.80. The company has a market capitalization of $11.21 billion, a P/E ratio of 12.01 and a beta of 0.52. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.28 and a current ratio of 4.41.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.28 by $0.08. The firm had revenue of $614.70 million during the quarter, compared to analyst estimates of $575.01 million. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. The company’s revenue was up 25.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.67 earnings per share. As a group, equities research analysts predict that United Therapeutics Co. will post 23.45 EPS for the current fiscal year.

Insider Buying and Selling

In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction that occurred on Friday, April 26th. The shares were sold at an average price of $235.20, for a total transaction of $846,720.00. Following the transaction, the chief executive officer now directly owns 130 shares of the company’s stock, valued at $30,576. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other United Therapeutics news, EVP Paul A. Mahon sold 6,000 shares of the company’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $215.31, for a total transaction of $1,291,860.00. Following the completion of the sale, the executive vice president now directly owns 36,599 shares in the company, valued at $7,880,130.69. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction dated Friday, April 26th. The shares were sold at an average price of $235.20, for a total value of $846,720.00. Following the transaction, the chief executive officer now directly owns 130 shares in the company, valued at $30,576. The disclosure for this sale can be found here. Insiders sold 140,590 shares of company stock worth $33,086,361 in the last quarter. 12.50% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

UTHR has been the topic of a number of analyst reports. StockNews.com lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, April 11th. Wedbush reissued an “outperform” rating and issued a $308.00 price target on shares of United Therapeutics in a report on Thursday, February 22nd. HC Wainwright reaffirmed a “buy” rating and set a $300.00 price objective on shares of United Therapeutics in a research note on Thursday, February 22nd. SVB Leerink started coverage on shares of United Therapeutics in a research note on Monday, February 5th. They issued an “outperform” rating and a $330.00 target price on the stock. Finally, The Goldman Sachs Group upgraded shares of United Therapeutics from a “sell” rating to a “neutral” rating and boosted their price target for the company from $213.00 to $215.00 in a research report on Monday, February 12th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $294.25.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.